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Trends box  
 TRAIL-induced complexes I and II both act as cell death-inducing and gene-
activatory signalling platforms 
 The core components of TRAIL-induced signalling, TRAIL-R1/2, FADD, 
caspase-8, RIPK1 and cFLIPL/S, are regulated by ubiquitination   
 Ubiquitin writers, erasers and binders such as TRAF2, cIAP1/2, LUBAC, A20, 
TABs and NEMO are major regulatory components in TRAIL-induced signalling 
complexes 
 Both, degradative (K48) and non-degradative (K63 and M1) poly-ubiquitination 
events control the TRAIL-induced signalling outcome 
 Tight regulation of the function and expression of TRAIL-induced signalling 
complex components by ubiquitination is required to ensure appropriate 
activation of downstream signalling outputs 
  Due to their decisive regulatory roles in mediating TRAIL signalling outputs in 
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ABSTRACT  9 
Despite its name, signalling induced by the tumor necrosis factor (TNF)-related 10 
apoptosis-inducing ligand (TRAIL) is versatile. Apart from eliciting cell death by both 11 
apoptosis and necroptosis, TRAIL can also induce migration, proliferation and 12 
cytokine production, in cancerous and non-cancerous cells. Unravelling the 13 
mechanisms regulating the intricate balance between these different outputs could 14 
therefore facilitate our understanding of the role of TRAIL in tissue homeostasis, 15 
immunity and cancer. Ubiquitination and its reversal, deubiquitination, are crucial 16 
modulators of immune receptor signalling. This review discusses recent progress on 17 
the orchestration of TRAIL signalling outcomes by ubiquitination of various 18 
components of the signalling complexes, our understanding of the molecular 19 









































































Ubiquitin: a central regulator of Death Receptor signalling 25 
Death Receptors (DRs) are members of the Tumor Necrosis Factor (TNF)-Receptor 26 
Superfamily (TNFR-SF) characterised by the presence of a C-terminal intracellular 27 
domain of 60-80 amino acids called the Death Domain (DD). DRs can mediate a 28 
variety of signalling outcomes, spanning from induction of cell death to survival, 29 
proliferation, differentiation, migration as well as cytokine production and are thus 30 
major players of immunity and tissue homeostasis. In humans, eight members of the 31 
TNFR-SF form part of the DR family: TNFR1, CD95 (Fas/APO-1), DR3, TRAIL-R1 32 
(DR4), TRAIL-R2 (DR5), DR6, EDAR and NGFR. This family can be further sub-33 
divided depending on the main signalling outcome triggered by these receptors, (i.e. 34 
the death inducers, like TRAIL-R1/2 and CD95, versus the gene activators, like 35 
TNFR1). Among the ligands of the DR family, TRAIL, identified based on its 36 
homology with CD95L [1, 2], has been of particular interest due to its unique ability of 37 
killing cancer cells without causing overt toxicity when used as a systemic drug [3, 4]. 38 
On the basis of this discovery several TRAIL-R agonists (TRAs) have been tested in 39 
clinical trials. Unfortunately, however, these first-generation TRAs have all failed due 40 
to lack of efficacy [5]. On the contrary, the CD95L/CD95 and TRAIL/TRAIL-R 41 
systems were also recognised as potent mediators of non-apoptotic signalling shortly 42 
following their respective discoveries [6, 7]; until recently studies exploring this 43 
signalling arm remained scarce. An increasing number of studies now demonstrate 44 
CD95’s pro-tumorigenic role in-vivo [8-12]. Similarly, important aspects of the biology 45 
of TRAIL in cancer have only recently been uncovered [13], e.g. the discovery of the 46 
pro-tumorigenic capacity of TRAIL to enhance migration, invasion and promote the 47 




































































17]. Thus, a deeper understanding of the regulation of the different outcomes of 49 
TRAIL-induced signalling is required in order to harness the biology of TRAIL for 50 
improved treatment of cancer and indeed other diseases, including auto-immune 51 
diseases [13, 18, 19]. 52 
Recently, various types of ubiquitination events (BOX 2) have emerged as crucial 53 
regulators of DR-mediated signalling. Ubiquitination involves the interplay of several 54 
actors (‘readers’, ‘writers’, ‘erasers’) which have most extensively been studied for 55 
the TNF/TNFR1 signalling system (Figure 1). TNF is a pro-inflammatory cytokine 56 
crucial in the response to infections, several auto-immune diseases as well as 57 
cancer-related inflammation [20]. Its signalling through TNFR1 involves the 58 
chronological and coordinated formation of two complexes, leading to different 59 
functional outcomes as first demonstrated by Micheau and Tschopp in 2003 [21]. 60 
Since then, we have learned a lot more about the formation of these complexes; in 61 
brief, binding of TNF to TNFR1 triggers the rapid formation of the TNFR1 signalling 62 
complex (TNFR1-SC; previously also referred to as TNF-RSC). Besides TNF and 63 
TNFR1, the TNFR1-SC contains TRADD, RIPK1, TRAF2, cIAP1/2, LUBAC and the 64 
IKK and TAB/TAK complexes. The latter two functional units trigger gene activation 65 
from this signalling complex. Importantly, recruitment of the TAB/TAK and IKK 66 
complexes to the TNFR1-SC relies on the recognition of K63- and M1-ubiquitin 67 
linkages by the ubiquitin binders, i.e. ‘readers’, TAB2/3 and NEMO. Whereas for the 68 
recruitment of the TAB/TAK complex only K63 chains are required, the recruitment of 69 
the IKK complex involves both, K63 and M1 linkages [22-24]. Ubiquitination events 70 
are also required for gene activation downstream of the TNFR1-SC. Indeed, 71 
association of the IKK complex with the TNFR1-SC activates IKKβ which in turn 72 




































































of the NF-κB subunits p50 and p65. Activated IKKβ also mediates the de novo 74 
generation of p50. This occurs via the phosphorylation of p105 [25], leading to p105 75 
ubiquitination by the E3-ligase complex KPC1 and subsequent partial proteasomal 76 
processing, resulting in the formation of p50 as a cleavage fragment of p105 [26]. 77 
The p50 and p65 NF-κB subunits then translocate to the nucleus, acting as dimers to 78 
promote transcription of genes mainly coding for cytokines and pro-survival proteins 79 
[26].  80 
As crucial as it is to induce gene activation, it is equally important to be able to switch 81 
it off again. The reversal of ubiquitination, mediated by so-called deubiquitinases 82 
(DUBs), is central to this activity. An important DUB in this regard is CYLD which has 83 
recently been shown to cleave both, K63- and M1-linked ubiquitin chains in the 84 
TNFR1-SC, thereby destabilizing this complex [27, 28]. However, the extent to which 85 
CYLD activity exerts a negative regulatory effect on TNF-induced gene-activatory 86 
signalling appears to be cell type-dependent [27, 29-32]. Defective ubiquitination 87 
within the TNFR1-SC, due to absence of cIAP1/2 or LUBAC, destabilizes complex I, 88 
impairs gene-activatory signalling and leads to the formation of the cytoplasmic 89 
complex II. This complex is thought to form around de- or at least less ubiquitinated 90 
components of complex I, such as TRADD and RIPK1, to which additional 91 
components are recruited including FADD, cFLIPL/S, caspase-8/10, RIPK3 and 92 
cytosolic RIPK1 [33-36]. Complex II acts as a Death-Inducing Signalling Complex 93 
(DISC), a term initially coined for the CD95-associated plasma membrane-bound 94 
complex; in the remainder of this review we will broaden the applicability of the term 95 
“DISC” to all complexes with death-inducing functionality.  96 
Depending on the cellular context, but especially the relative expression of caspase-97 




































































Whilst cFLIPS completely prevents caspase-8 activation, the cFLIPL/caspase-8 99 
heterodimer is able to cleave RIPK1 and RIPK3 [37-39], two kinases required for 100 
necroptosis. Thereby, cFLIPS restricts apoptosis but promotes necroptosis whereas 101 
cFLIPL can limit necroptosis. As further explained in the next section, the expression 102 
level of cFLIPL can modulate its specific role in DR-induced cell death. Downstream 103 
of RIPK1 and RIPK3, the pseudo-kinase MLKL is also required for necroptosis. With 104 
respect to cell death signalling, ubiquitination and deubiquitination events are 105 
particularly crucial in regulating the transition from complex I to complex II and, 106 
thereby, exert an important role in orchestrating the TNF-induced signalling outcome 107 
(Figure 2).  108 
Whereas the role of ubiquitination as a master regulator of TNFR1 signalling has 109 
been established for years, the impact of this post-translational modification (PTM) 110 
on additional DR signalling pathways is just on the brink of being uncovered [32, 40, 111 
41]. TRAIL/TRAIL-R-mediated signalling has recently received particular attention in 112 
this regard and will thus be the main focus of this review (Key table 1). 113 
Regulation of TRAIL-induced cell death by ubiquitin 114 
TRAIL binds to four different cell surface receptors referred to as TRAIL-R1 to 115 
TRAIL-R4. Only TRAIL-R1 (also known as death receptor 4; DR4) and TRAIL-R2 116 
(DR5) contain a cytoplasmic DD capable of recruiting FADD, a requirement to 117 
mediate cell death induction. TRAIL-R3 is a GPI-anchored receptor and TRAIL-R4, 118 
whose cytoplasmic domain only contains a truncated DD, is not capable of inducing 119 
cell death but can induce the activation of NF-B [42].  120 
Upon binding to TRAIL-R1/2, TRAIL induces the formation of two complexes, the 121 




































































complex II devoid of TRAIL-Rs. Whilst the basic scheme thereby mirrors complex 123 
formation in TNF/TNF-R1 signalling, it was recently shown that, unlike in TNF 124 
signalling, both TRAIL-induced signalling complexes can serve as DISCs [43]. 125 
Notably, the finding that complexes I and II can both act as DISCs was initially 126 
reported for CD95 signalling [44, 45]. TRAIL can induce cell death via two different 127 
modalities: the well-defined, caspase-dependent process of apoptosis [1, 2] and a 128 
more recently discovered, caspase-independent process known as necroptosis. As 129 
in TNF/TNFR1 signalling, TRAIL-induced necroptosis requires the kinase activities of 130 
RIPK1 and RIPK3 [43, 44, 46-48]. Importantly, specific and distinct ubiquitination 131 
events modulate the function of several components of this pathway, thereby 132 
decisively influencing the ultimate outcome of TRAIL-induced signalling (Figure 3). 133 
Regulation of TRAIL-induced death by ubiquitination of TRAIL-R1/2 and FADD 134 
Degradative ubiquitination events regulate both TRAIL-R1 and TRAIL-R2. In 135 
particular, MARCH8 was suggested to mediate degradative ubiquitination of TRAIL-136 
R1 on K273 [49]. However, further experimental evidence is necessary to ascertain 137 
the E3-ligase role of endogenous MARCH8 in directly ubiquitinating TRAIL-R1. 138 
Several studies point to differential roles of TRAIL-R1 and TRAIL-R2 in apoptotic and 139 
non-apoptotic signalling [16, 50-52] and it remains to be determined to which extent 140 
distinct PTMs and the resulting interactomes account for these functional 141 
differences. 142 
Upon TRAIL stimulation, FADD directly binds to TRAIL-R1/2 by DD-mediated 143 
homotypic interactions and is required for the recruitment of all downstream 144 
components of complex I including RIPK1, caspase-8/10, cFLIP and LUBAC [43, 53-145 




































































which drives its proteasomal degradation, thereby regulating FADD protein levels 147 
[56]. Accordingly, MKRN1 prevents apoptosis induction by TRAIL, CD95L and TNF 148 
in vitro and interferes with TRAIL-induced cell death in a breast cancer xenograft 149 
model in vivo. However, the lysine residue(s) targeted by MKRN1 on FADD 150 
remain(s) unknown. As FADD is required for all DD-dependent TRAIL- as well as 151 
CD95L-induced signalling outcomes [7, 14, 46, 57-60], MKRN1 also likely dampens 152 
cytokine production and necroptosis induced by these two DR ligands. By contrast, 153 
TNF-mediated gene induction is likely to be unaffected by MKRN1 due to the lack of 154 
a role for FADD therein, whilst this E3-ligase would promote TNF-induced 155 
necroptosis given the role of the FADD/caspase-8/cFLIPL complex in limiting this 156 
type of cell death [39, 61, 62].  157 
Regulation of TRAIL-induced death by ubiquitination of caspase-8 158 
Binding of FADD to trimerized TRAIL-R1 and TRAIL-R2 exposes the Death Effector 159 
Domain (DED) of FADD, leading to homotypic interaction with the DEDs of caspase-160 
8 and cFLIPL/S. DISC-recruited caspase-8 then nucleates the homo-oligomerization 161 
of caspase-8 as well as its hetero-oligomerization with caspase-10 and cFLIPL/S, 162 
forming structures coined DED-mediated filaments [63-67]. Recent studies have 163 
uncovered the roles of PTMs, in particular of ubiquitination, in modulating the 164 
activation of the initiator caspase-8. 165 
Jin et al. reported that the E3-ligase Cullin-3 mediates K48/K63 ubiquitination of 166 
caspase-8 on K461 within the p10 subunit. This occurs upon TRAIL stimulation, in 167 
an RBX1-dependent manner within complex I [68]. The ubiquitin-binding protein p62 168 
recognizes Cullin-3-ubiquitinated caspase-8, promoting caspase-8 oligomerization, 169 




































































induced caspase-8 activation. Jin et al. also showed that overexpression of the DUB 171 
A20 reverses Cullin-3-mediated ubiquitination of caspase-8, thereby reducing 172 
caspase-8 activation [68].  173 
Unlike Cullin-3-mediated ubiquitination of caspase-8, other ubiquitination events of 174 
caspase-8 appear to limit its activation. The E3-ligase HECTD3, for example, 175 
reduces caspase-8 activation upon TRAIL, TNF or anti-CD95 treatment; hence 176 
HECTD3 decreases TRAIL-induced apoptosis in MDA-MB-231 cells [69]. Upon 177 
overexpression, HECTD3 forms a complex with caspase-8 and catalyzes its K63-178 
linked ubiquitination on K215, thereby preventing caspase cleavage and p18 subunit 179 
release. Since endogenous HECTD3 is not recruited to TRAIL complex I in a 180 
stimulation-dependent manner, the degree to which the proposed mechanism 181 
accounts for HECTD3’s role in limiting cell death remains to be determined.  182 
Subsequent to Cullin-3-mediated ubiquitination of caspase-8, TRAF2 is required for 183 
the K48-linked ubiquitination of caspase-8 on K224/229/231 within the p18 domain. 184 
This leads to the proteasomal degradation of caspase-8 and the termination of 185 
TRAIL-R- and CD95-mediated apoptotic signalling [70]. The possibility for TRAF2 to 186 
act as an E3-ligase has been contested from a structural point of view [71-73]. 187 
Intriguingly, Gonzalvez et al. provide in-vitro data on TRAF2 ubiquitinating the p18 188 
subunit of caspase-8 and show that TRAF2’s RING domain is required for limiting 189 
TRAIL-induced caspase-8 activation and cell death [70-73]. Independently of 190 
whether its E3-ligase activity is required or not, current accounts argue for an anti-191 
apoptotic role of TRAF2, a finding that is in line with TRAF2’s RING domain being 192 




































































It was recently demonstrated that caspase-8 is also linearly ubiquitinated upon 194 
TRAIL stimulation [43]. LUBAC, which forms part of complexes I and II in TRAIL 195 
signalling, limits caspase-8 activation therein consequently inhibiting apoptosis. 196 
Intriguingly, LUBAC promotes recruitment of A20 to these complexes [43]. Thus, it 197 
would be interesting to define whether the putative eraser role of A20 towards K63-198 
chains on caspase-8 influences HOIP’s role in TRAIL signalling. HOIP-deficiency 199 
also restricts CD95L-induced cell death in Mouse Embryonic Fibroblasts (MEFs) and 200 
primary hepatocytes, whilst LUBAC has so far not been reported to form part of 201 
CD95 signalling complexes [75, 76]. In line with their roles as negative regulators of 202 
TRAIL-induced apoptosis in complex I and II, TRAF2, LUBAC and A20 as well as the 203 
accumulation of linear chains are relatively late events in comparison to 204 
FADD/caspase-8 association, indicative of a role in termination of caspase activation 205 
[43, 70, 77]. 206 
As is often the case in biology, whilst these recent discoveries bring answers to 207 
certain questions, they also pose new ones (see outstanding questions); e.g. it 208 
remains to be defined to which extent the different caspase-8 ubiquitination events 209 
are required for enabling and regulating caspase-8 oligomerization and activation. 210 
Furthermore, the impact of ubiquitination events on the stoichiometry of the caspase-211 
8/caspase-10/cFLIPL/S hetero-oligomers would be interesting to address in a cellular 212 
context. It also remains to be determined how K63-linked ubiquitin modifications of 213 
caspase-8 by Cullin-3 versus HECTD3 differ from each other molecularly, so as to 214 
achieve the above-mentioned opposite outcomes with regards to caspase activation 215 
and cell death [68, 69]. Intriguingly, although caspase-10 is efficiently activated in 216 
complex I [78, 79] and possesses the target site K461, it does not appear to be 217 




































































overexpression, Sprick et al. found that caspase-10 cannot compensate for caspase-219 
8 loss in mediating TRAIL- or CD95L-induced apoptosis in caspase-8-deficient 220 
Jurkat cells [78-80]. Interestingly, a recent study by Horn et al. elegantly 221 
demonstrates that caspase-10 acts as a negative regulator of CD95L-induced 222 
apoptosis [81]. Defining whether the endogenous stability, oligomerization and/or 223 
activation of caspase-10 is influenced by ubiquitination could be informative to 224 
further understand its role in regulating the different outcomes of DR signalling.  225 
Regulation of TRAIL-induced death by ubiquitination of cFLIPL/S 226 
The long and short isoforms of cFLIP are major regulators of TRAIL-induced 227 
signalling. Contrary to the cFLIPs/caspase-8 heteromer, the cFLIPL/caspase-8 228 
heteromer is able to cleave RIPK1, RIPK3 and CYLD and can therefore restrict 229 
necroptosis [37-39, 82]. Importantly, the ratio of cFLIPL, cFLIPS and caspase-8 230 
regulates the degree of DED-mediated filament extension and, thereby, the extent of 231 
caspase-8 activation [67]. Indeed, cFLIPS prevents caspase-8 activity by abrogating 232 
DED-filament elongation thus preventing apoptosis. When expressed at low levels, 233 
cFLIPL promotes DED-filament elongation and would hence favour apoptosis. On the 234 
contrary, high expression of cFLIPL dampens caspase-8 oligomerisation which would 235 
account for its role in restricting apoptosis.  236 
In accordance with these important, yet distinct roles in fine-tuning cell death 237 
signalling, the protein levels of cFLIPL and cFLIPS are tightly but differentially 238 
regulated by PTMs with ubiquitination featuring most prominently amongst them. Itch 239 
is a HECT-E3 ligase reported to specifically interact with cFLIPL, mediating its K48-240 
linked ubiquitination and proteasomal degradation upon TNF stimulation in a JNK-241 




































































and cFLIPs and to thereby promote TRAIL-induced apoptotic signalling [84, 85]. 243 
Several lysines are targeted to promote proteasomal degradation of cFLIPL and 244 
cFLIPS, but the impact of their mutation on TRAIL-induced signalling remains to be 245 
assessed [86-88]. Conversely, the DUB USP8 interacts with cFLIPL via its caspase-246 
like domain, leading to its deubiquitination, thus preventing the proteasomal 247 
degradation of cFLIPL [89]. In accord, USP8 limits TNF-, CD95L- and TRAIL-induced 248 
apoptosis, the latter also in-vivo [89]. USP8 might also modulate the stability of 249 
cFLIPL and cFLIPs indirectly by deubiquitinating Itch [90]. The involvement of USP8 250 
in DR-induced necroptosis and gene-activatory signalling remains elusive. Whether 251 
and to which extent non-degradative ubiquitination of cFLIPL and/or cFLIPS also 252 
influences their respective functions in DR-signalling would also be interesting to 253 
explore.  254 
As highlighted above, we are only beginning to grasp the complexity of the 255 
regulatory roles different E3s and DUBs exert on the function and stability of key 256 
components of the TRAIL signalling pathway. This points out a major research 257 
avenue that will likely lead to exciting fundamental, but potentially also 258 
therapeutically relevant findings with regards to TRAIL signalling which may extend 259 
to other immune receptor signalling systems (see Outstanding questions).  260 
RIPK1 and RIPK3 are ubiquitinated during TRAIL-induced death 261 
RIPK1 can be detected in both, complex I and II of TRAIL signalling to which it is 262 
recruited in a FADD/caspase-8-dependent manner. In both complexes RIPK1 is 263 
present as a heavily ubiquitinated component. Besides its role as a regulator of 264 
caspase-8 ubiquitination [68], A20 might limit TRAIL-induced apoptosis by K63-265 




































































glioblastoma cells [91]. It is, however, puzzling that the K63-DUB A20 would also act 267 
as an E3 ligase that forms K63-linked chains.  Hence, the mechanism by which 268 
caspase-8 recognizes, and is inhibited by, K63-decorated RIPK1 remains to be 269 
defined in more detail.  270 
In addition to caspase-8, also RIPK1 is a LUBAC target upon TRAIL stimulation [43]. 271 
Similar to recent findings in TNFR1, IL1R and TLR1/2/3 signalling [92], the linear 272 
chains generated upon TRAIL stimulation are added on top of other chain types. As 273 
such, depletion of cIAP1/2 by a SMAC mimetic compound, which sensitizes cells to 274 
TRAIL- and CD95L-induced death, not only impairs recruitment of LUBAC and A20 275 
to TRAIL complex I but also substantially reduces RIPK1 ubiquitination in this 276 
complex [43]. The latter event was previously also reported for complex I of CD95 277 
signalling [44]. Thus, cIAP1/2 enable LUBAC recruitment and likely directly catalyse 278 
the formation of ubiquitin chains on RIPK1 which form the basis for linear chain 279 
addition, potentially in various DR signalling pathways. In the context of TNF 280 
signalling, LUBAC is currently thought to prevent death by limiting the formation of 281 
complex II through stabilisation of the TNFR1-SC [28, 75, 93-95]. Similarly, following 282 
TRAIL stimulation, RIPK1 also accumulates in the complex II that forms in cells 283 
which are deficient in HOIP or only deficient in its catalytic activity [43]. However, the 284 
model according to which ubiquitination events on RIPK1 solely prevent its transition 285 
from complex I to II in TNF signalling might well be too simplistic. Indeed, under 286 
specific necroptosis-triggering conditions RIPK1 is heavily ubiquitinated by M1 and 287 
K63-chains in the necrosome [96]. Herein, the K63 chains on RIPK1 appear to 288 
contribute to necroptosis induction whilst the role of the M1 chains remains enigmatic 289 
[97]. Intriguingly, HOIP’s catalytic activity is not absolutely required for limiting 290 




































































prevents TRAIL-induced necroptosis and the association of heavily ubiquitinated 292 
RIPK3 and phosphorylated MLKL with a FADD/caspase-8/RIPK1-containing 293 
necroptosis-inducing complex; again independently of its activity [43]. The HOIP-294 
dependent factors which modulate RIPK1 kinase-dependent apoptosis and 295 
necroptosis as well as RIPK3 and RIPK1 ubiquitination in complex II remain to be 296 
defined. Interestingly, depletion of cIAP1/2 or knock-down of TRAF2 also sensitize 297 
cells to TRAIL- and CD95L-induced necroptosis [44, 47]. The mechanism underlying 298 
the effect of TRAF2 or cIAP depletion in CD95 signalling would require an in-depth 299 
investigation. In TRAIL signalling, however, it is likely that part of this sensitization 300 
results from the absence of LUBAC recruitment to complex I and II. 301 
The regulation of TRAIL-mediated non-death signalling by ubiquitin 302 
TRAIL and CD95L can also promote cell survival, proliferation, migration, cytokine 303 
secretion and immuno-modulation [8-12, 14, 16, 59, 98-103]. Studies deciphering the 304 
involvement of ubiquitination in TRAIL- and CD95L-mediated non-apoptotic 305 
signalling remain scarce and have mainly focussed on cytokine production. TRAIL-306 
induced cytokine production involves transcription factors such as NF-ĸB and 307 
members of the MAPK families such as JNK, ERK1/2 and p38 (BOX 2), which are 308 
known modulators of TNF-induced pro-inflammatory signalling [7]. Whilst MAPKs 309 
can participate in cytokine production, canonical activation of NF-κB appears to be 310 
the most prominent and consistently activated pathway driving TRAIL- and most 311 
likely also CD95L-induced cytokine production [14, 43, 59, 77, 100, 101, 104]. In 312 
accordance, TAK1 and IKKα/β, which are crucial in NF-κB activation, are required for 313 
TRAIL-induced cytokine production [14, 43, 77]. TRAIL can trigger NF-κB activation 314 
by binding to TRAIL-R1, TRAIL-R2 and TRAIL-R4 [7, 42]. Thereby, TRAIL signalling 315 




































































CXCL1, CXCL5 and NAMPT and anti-apoptotic genes such as cFLIP and Mcl-1 [14, 317 
105]. Hence, gene-activatory signalling can facilitate resistance to TRAIL-induced 318 
death in cancer cells [106]. 319 
In resistant cancer cells TRAIL and CD95L elicit the secretion of a similar repertoire 320 
of cytokines which, in the context of TRAIL-signalling, can modulate the immune-321 
microenvironment to promote tumorigenesis [14, 59, 60]. TRAIL-induced gene-322 
activatory signalling has long been associated with the cytosolic complex II, a 323 
complex which was recently dubbed the “FADDosome” [77, 99]. However, also the 324 
membrane-associated complex I of TRAIL signalling can induce gene activation [43]. 325 
Both complexes contain FADD, caspase-8, RIPK1 and the IKK complex, all of which 326 
are core factors for mediating TRAIL-induced gene activation [43, 77, 107]. 327 
FADD and Caspase-8 are essential for TRAIL-induced gene activation 328 
In contrast to TNF signalling, the bona fide death ligands TRAIL and CD95L mediate 329 
gene-activatory signalling via FADD and caspase-8, which are also the core 330 
components facilitating death ligand-induced apoptosis [60]. The apical adaptor 331 
FADD is essential for the formation of both, complex I and II and is therefore also 332 
crucial for TRAIL- and CD95L-mediated gene-activatory signalling and cytokine 333 
production [14, 43, 59, 60, 99, 101, 108, 109]. Downstream of FADD, caspase-8 334 
recruits several components in turn promoting TAB/TAK and IKK complex 335 
recruitment and activation [43, 77]. Therefore, contrary to the situation in TNF 336 
signalling, caspase-8 is required for TRAIL- and CD95L-induced gene activation and 337 
cytokine production [14, 43, 99, 101, 108, 110]. Intriguingly, the proteolytic activity of 338 
caspase-8 is dispensable herein and, if anything, limits rather than promotes 339 




































































ability to promote cell death and cleave RIPK1, a component of the TRAIL signalling 341 
complexes which induces cytokine production in certain cell types [14, 60, 112].  342 
Apart from FADD, caspase-8 and RIPK1, the additional DED-containing proteins 343 
caspase-10 and cFLIP also influence TRAIL-induced gene activation [81, 109]. 344 
Unlike caspase-8, caspase-10 is not essential for TRAIL-induced cytokine production 345 
but contributes to it [77]. Although the underlying mechanism currently remains 346 
elusive for TRAIL signalling, with regard to CD95L-induced signalling it was recently 347 
shown that the activity of caspase-10 is dispensable for its function in gene activation 348 
[81]. 349 
Knockdown of cFLIPL and cFLIPS facilitates IKK recruitment to complex I of TRAIL 350 
signalling and elevates cytokine induction upon CD95L treatment [43, 60, 113]. 351 
However, owing to their differential abilities in enabling caspase-8 oligomerization 352 
and activity [67], the specific roles of cFLIPL versus cFLIPS in cytokine production 353 
could actually oppose each other, an aspect which remains to be resolved. 354 
Regulation of TRAIL-mediated gene activation by E3 ligases 355 
Apart from modulating apoptosis signalling, E3 ligases also regulate the gene-356 
activatory outputs of TRAIL signalling as two core signalling components which are 357 
involved in TRAIL-induced gene activation, caspase-8 and RIPK1, are substantially 358 
targeted by ubiquitination [43, 77]. As explained above, the E3 ligases cIAP1/2 and 359 
HOIP are recruited to both TRAIL signalling complexes in a FADD/Caspase-8-360 
dependent manner. Also, both TRAF2 and cIAP1/2 enhance TRAIL- and CD95L-361 
mediated gene activation [43, 59, 77, 114]. As such, knockout of TRAF2 in cFLIP-362 
expressing cells, as well as transient TRAF2 knockdown attenuated NF-κB 363 




































































context of TNF signalling, TRAF2-cIAP1/2-mediated ubiquitination of RIPK1 365 
facilitates NF-κB activation [116-119] wherein TRAF2’s gene-activatory functions rely 366 
on its ability to recruit cIAP1/2 [74]. In line with a gene-activatory role for TRAF2 as a 367 
scaffold in TRAIL signalling, depletion of cIAP1/2 strongly decreased RIPK1 368 
ubiquitination, IKK recruitment, NF-κB activation and blunted TRAIL-mediated 369 
cytokine secretion, whilst TRAF2 recruitment remained unaffected [14, 43]. Thus, 370 
TRAF2 likely promotes TRAIL-induced cytokine production by serving as the 371 
recruitment platform for cIAPs, as previously shown for TNF signalling [74]. 372 
Downstream of TRAF2, cIAP1/2 are also required for the recruitment of LUBAC to 373 
TRAIL complex I [43]. Although the molecular mechanism remains unexplored, 374 
HOIP-deficiency was demonstrated to decrease CD95L-induced NF-κB activation in 375 
primary murine hepatocytes [76].  376 
LUBAC is decisive for TNFR1-induced gene-activatory signalling by mediating 377 
TNFR1-SC stabilization via linear ubiquitination of TRADD, RIPK1, NEMO and the 378 
TNFR1 [93, 94]. Yet, whilst FADD and caspase-8 are dispensable for recruitment of 379 
cIAPs and LUBAC to the TNFR1-SC, their recruitment to the TRAIL-R-SC requires 380 
FADD and caspase-8 [43, 120]. Within the TRAIL-induced complexes I and II, 381 
LUBAC promotes recruitment of the IKK complex and, thereby, mediates TRAIL-382 
induced activation of NF-κB, as consistently found in various cancer cell lines and in 383 
several non-transformed cell types [43]. As LUBAC is required for TRAIL-induced 384 
secretion of cytokines and chemokines, this E3 ligase is likely of physiological 385 
relevance for TRAIL-mediated modulation of cancerous and non-cancerous tissue 386 
homeostasis [14].   387 
In the TRAIL-induced signalling complexes HOIP linearly ubiquitinates caspase-8 388 




































































ensuing NF-κB activation [43]. It is important to note, however, that absence of HOIP 390 
neither completely abrogates TRAIL- nor TNF-induced NF-κB activation [28, 43, 94]. 391 
NEMO, the regulatory subunit of the IKK complex, contains a UBD in ABIN and 392 
NEMO (UBAN) domain, which has a significantly higher affinity for M1- than for K63-393 
linked chains, as well as a zinc finger (ZF) which preferentially recognizes K63 394 
chains. Together, this confers dual affinity for M1- and K63-linkages to NEMO [121, 395 
122]. The coordinated formation and recognition of different linkages, formed by 396 
LUBAC, cIAP1/2 and possibly additional E3 ligases in turn enables the recruitment of 397 
the IKK complex to the TRAIL-R-SC, consequently activating the NF-κB pathway. 398 
Mechanistically, LUBAC might also promote TRAIL-induced cytokine production by 399 
limiting the activation of caspase-8 as explained above. Interestingly, HOIP itself is 400 
cleaved by caspase-8 upon TRAIL stimulation, although cleavage does not affect its 401 
role in TRAIL-induced apoptosis or gene activation, at least in vitro [43].  402 
Regulation of TRAIL-mediated gene activation by deubiquitinases 403 
Although the impact of deubiquitination events within TRAIL-induced signalling 404 
complexes on gene-activatory signalling output remains to be unravelled, certain 405 
functional insight has already been gained especially regarding the DUBs A20 and 406 
CYLD. Similar to its role in TNF signalling [28, 123], A20 limits TRAIL-induced IL-8 407 
and IL-6 secretion [77] and its presence in both TRAIL signalling complexes was 408 
recently shown to be dependent on HOIP [43, 77]. This is likely due to a requirement 409 
of HOIP-catalysed M1 chains for A20 recruitment to these complexes, as shown for 410 
this DUB’s recruitment to the TNFR1-SC [28, 124, 125]. Whether A20’s effect on 411 
TRAIL signalling specifically requires its DUB activity or, as in TNF signalling, is 412 
owed to its function as a binder/occupier of linear ubiquitin linkages [28, 124, 125], 413 




































































Similar to A20, CYLD is recruited to complexes I and II of TRAIL signalling in a 415 
HOIP-dependent manner [43]. Whilst not formally proven, it is again highly likely that, 416 
as in the case of the TNFR1- and NOD2-SCs, CYLD recruitment to these complexes 417 
also relies on its interaction with HOIP via SPATA2 [29, 126-128]. CYLD might limit 418 
TRAIL-induced NF-κB signalling as shown in overexpression systems [129, 130]. 419 
However, CYLD was only detected in the TRAIL-induced signalling complexes upon 420 
caspase inhibition. Accordingly, CYLD does not affect TRAIL-mediated cytokine 421 
production when caspases are active, possibly because caspase-8-mediated 422 
cleavage can inactivate CYLD [43, 77]. It remains to be determined whether 423 
conditions of caspase inhibition (e.g. viral infections) would render CYLD an efficient 424 
inhibitor of TRAIL-induced gene activation.  425 
Concluding remarks and perspectives 426 
The signalling pathways induced by TRAIL and TNF are initiated via their respective 427 
receptors and regulated via multiple common proteins, yet the two systems’ 428 
respective primary signalling outcomes oppose each other as TRAIL’s primary 429 
signalling output is cell death whereas that of TNF is gene activation. This feature 430 
was long thought to result from opposite bifurcations in the respective signalling 431 
pathways. Indeed, receptor-associated complexes were thought to drive cell death or 432 
gene activation from the respective complexes I of TRAIL and TNF signalling. 433 
Secondary cytoplasmic signalling complexes would in turn trigger the remaining 434 
signalling outcomes, i.e. cell death for complex II of TNF signalling and gene 435 
activation for complex II of TRAIL signalling. Recent findings, however, implicate 436 
ubiquitination in specifically modulating the formation and function of these different 437 




































































In the context of TNF signalling, these studies have highlighted the importance of 439 
ubiquitination events in controlling the transition from the gene-activatory TNFR1-SC 440 
to the death-inducing complex II. Importantly, in the case of TRAIL signalling, the 441 
study of signal modulation by ubiquitin has revealed that gene activation and cell 442 
death are not induced by spatially distinct signalling complexes, but that they are 443 
instead fine-tuned by ubiquitination events within TRAIL complexes I and II which 444 
can both function as DISCs and as gene-activatory platforms [43]. Hence, 445 
ubiquitination events control the delicate balance between apoptosis, necroptosis 446 
and cytokine production in distinct ways in TRAIL- versus TNF-induced signalling. 447 
This said, we are only beginning to understand the precise molecular events and 448 
mechanisms at heart of the distinct regulatory processes that are responsible for the 449 
differences in signalling outcome (see outstanding questions). The expanding 450 
availability of sophisticated tools in studying ubiquitination and deubiquitination 451 
events in ever more detail and, at the same time, on the proteomic scale [131-134], 452 
offers the unique opportunity to decipher the complex ubiquitin code that regulates 453 
TRAIL versus TNF signalling and identify the distinguishing hallmarks between them. 454 
Whilst historically mainly disregarded as druggable targets [135], specific therapeutic 455 
targeting of the proteins involved in modulating the ubiquitin code is now beginning 456 
to become reality [135, 136]. Since TRAIL/TRAIL-R signalling is implicated in tumor 457 
biology, inflammation and immunity, further understanding of the readers, writers and 458 
erasers of TRAIL’s ubiquitin code will likely provide an opportunity for the 459 
identification of novel biomarkers and/or clinical targets for harnessing the 460 
TRAIL/TRAIL-R system therapeutically towards the treatment of various diseases 461 
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Figure legends  799 
Figure 1. Ubiquitin chain types 800 
Polyubiquitin chains consist of ubiquitin monomers which are joined via isopeptide or 801 
peptide bonds to form non-linear or linear chains, respectively. Conjugation occurs 802 
between the C-terminal carboxyl group of the incoming monomer and a specific ε-803 
amino Lysine (K) or the N-terminal Methionine (Met 1) group of the proximal ubiquitin 804 
monomer; the latter linkage defines the structure of the ubiquitin chain and 805 
determines its respective functionality. Hybrid, also referred to as mixed ubiquitin 806 
chains, for example composed of both K63- and M1-linked chains, have also been 807 
identified and play major roles in regulating multiple signalling pathways [137]. 808 
 809 
Figure 2. Regulation of TNF signalling by ubiquitination 810 
TNF binding triggers the oligomerization of TNFR1, enabling recruitment of the 811 
adaptor TRADD and the kinase RIPK1 by DD-mediated homotypic interactions. 812 
Next, TRADD recruits the RING-domain containing protein TRAF2, which recruits 813 
the E3-ligases cIAP1/2 that in turn ubiquitinate themselves and several other 814 
components of the TNFR1-SC. These ubiquitin chains provide a platform for 815 
recruitment of the TAB/TAK complex and the Linear Ubiquitin chain Assembly 816 
Complex (LUBAC). By targeting RIPK1, TRADD and TNFR1, LUBAC facilitates the 817 
recruitment and activation of the IKK complex. This initial complex, referred to as the 818 
TNFR1-SC or complex I of TNFR1 signalling, drives the activation of MAPKs (JNK, 819 
p38 and ERK) and the canonical NF-B pathways. These pathways, with NF-B at 820 
the forefront, in turn promote the transcription of pro-inflammatory cytokines and 821 




































































also formed upon TNF stimulation. This complex II is composed of de-, or at least 823 
less ubiquitinated components of complex I, such as TRADD and RIPK1, to which 824 
additional components are recruited including FADD, cFLIPL/S, caspase-8/10, RIPK3 825 
and cytosolic RIPK1. Upon deficiency of crucial ubiquitin modulators, such as cIAPs 826 
or LUBAC, the stability of the TNFR1-SC can be compromised, resulting in 827 
dampening of gene-activatory signalling and enhanced complex II formation. 828 
Complex II can act as a DISC, from which both necroptotic and apoptotic signalling 829 
emerge depending in particular on the relative abundance of the different cFLIP 830 
isoforms. Therefore, complex II triggers a classical caspase-8-dependent apoptosis 831 
or a caspase-independent necroptosis, which relies on the activation of the kinases 832 
RIPK1, RIPK3 and the pseudo-kinase MLKL. 833 
 834 
Figure 3. Regulation of TRAIL signalling by ubiquitination 835 
Binding of TRAIL to TRAIL-R1/2 triggers the formation of the TRAIL-R-associated 836 
complex I. Within complex I, multiple ubiquitination events control the induction of 837 
apoptosis and gene-activatory signalling. For example, addition of K63-chains on 838 
caspase-8 by Cullin-3 promotes activation, whilst TRAF2-dependent K48-839 
ubiquitination triggers the proteasomal degradation of this protease. Downstream of 840 
FADD, caspase-8 and cIAP1/2, LUBAC linearly ubiquitinates both caspase-8 and 841 
RIPK1 in complex I, thereby favouring A20 recruitment, limiting caspase-8 activation 842 
and promoting NF-κB activation which is the main driver of ensuing cytokine 843 
production. A second TRAIL-R-devoid, cytosolic complex, complex II, is detected 844 
upon TRAIL stimulation. The composition of complex II is very similar to that of 845 




































































Similarly to complex I, these ubiquitination events dictate the prevailing signalling 847 
outcome. Under certain circumstances, e.g HOIP deficiency and caspase inhibition, 848 
RIPK3 and MLKL are recruited to this secondary complex and induce necroptosis. 849 
Whether RIPK3 and MLKL may also be recruited and activated within complex I 850 
remains to be investigated. cFLIP isoforms tightly and differentially regulate TRAIL 851 
signalling, likely owing to their different abilities to control DED-protein containing 852 
filament formation (not shown here). In addition to ubiquitination events within 853 
complex I and II, the basal levels of several core components of TRAIL signalling, 854 
e.g TRAILR1/2, FADD and cFLIPL/S, are tightly regulated by degradative 855 
ubiquitination driven by several E3-ligases (not represented here). 856 
BOX 1: Role of endogenous TRAIL/TRAIL-R signalling in cancer  857 
The TRAIL/TRAIL-R system can elicit the induction of cell death and of gene 858 
activation. Mice deficient for TRAIL or TRAIL-R are viable, fertile and do not exhibit 859 
any overt phenotype [138, 139]. However, TRAIL signalling has been implicated in 860 
diverse roles upon pathological challenge, ranging from immune-surveillance in anti-861 
viral and anti-tumor defence to tumor-supportive effects, including modulation of  the 862 
tumor microenvironment [13].  863 
Regarding immune-regulatory effects, natural killer (NK) cells in particular utilize 864 
surface TRAIL to promote their cytolytic antiviral and anti-tumor effector functions; 865 
more extensively reviewed elsewhere  [140, 141]. For regulatory T cells (Tregs), 866 
TRAIL expression can also establish immune tolerance by eliciting potent immune-867 
suppressive functions, thereby enhancing survival of mice in an allogeneic skin graft 868 
model [142]. Regarding functionality of endogenous TRAIL in tumor physiology, 869 




































































TRAIL/TRAIL-R system [13]. TRAIL knockout mice exhibited enhanced tumor 871 
burden upon transplantation with A20 B cell lymphoma in comparison to wildtype 872 
counterparts [3, 139]. In accordance, surface expression of TRAIL on liver NK cells 873 
enables TRAIL-mediated anti-tumor immune surveillance; particularly regarding 874 
metastasis suppression [140]. Indeed, TRAIL-deficient mice were more susceptible 875 
to experimental liver metastasis [139, 143]. This metastasis-suppressive effect 876 
results from detachment-induced sensitization to TRAIL-mediated apoptosis in 877 
metastasizing tumor cells [144].  878 
Dependent on the oncogene mutation status, TRAIL can, however, also promote the 879 
formation of metastases in TRAIL apoptosis-resistant cancer cells [15, 16]. As such, 880 
cancer cell-endogenous mTRAIL-R expression promotes progression, invasion and 881 
metastasis in autochthonous KRAS-driven murine pancreatic and lung cancer 882 
models [16]. Next to cell-autonomous roles, endogenous TRAIL/TRAIL-R signalling 883 
mediates cytokine production, thereby modulating the composition of the tumor 884 
immune microenvironment, in a FADD/caspase-8-dependent manner. As such, 885 
endogenous TRAIL-signalling was recently shown to promote the accumulation of 886 
tumor-supportive M2-like myeloid cells via a CCL2/CCR2 axis [14, 16]. 887 
BOX 2: Regulators of the ubiquitin code  888 
Ubiquitination is the attachment of the C-terminal glycine residue of ubiquitin to the 889 
epsilon-amino-group of a lysine residue of a substrate. This process is mediated by 890 
the coordinated action of three classes of ‘writer’ enzymes, the E1, E2 and E3. 891 
Ubiquitin possesses seven lysines (K) which are also targeted for ubiquitination, 892 
leading to the formation of poly-ubiquitin chains. The N-terminal methionine (M1) of 893 




































































exclusively generated by the specific E3-Ligase, Linear ubiquitin chain assembly 895 
complex (LUBAC). LUBAC is composed of HOIL-1, SHARPIN and the catalytically 896 
active component HOIP. Poly-ubiquitin linkages are categorized depending on the 897 
modified residue of the target ubiquitin, which designates chain functionality. Thus 898 
K6, K11, K27, K29, K33, K48, K63 and M1 linkages can be distinguished and 899 
differentially combined on a given target or residue forming a ‘ubiquitin code’ [137] 900 
(Figure 1).  901 
Chain recognition occurs by Ubiquitin Binding Domains (UBD) present in multiple 902 
‘reader’ proteins, which elicit crucial complex modulating functions, deciphering the 903 
ubiquitin code. In the context of TNF signalling, K63 and M1 chains recruit the 904 
TAB/TAK and the IKK complex (readers), followed by K48 ubiquitination and 905 
consequent proteasomal degradation of I-κB, consequently ensuring optimal gene 906 
activation. Hence, ubiquitination modulates the function and fate of both, the 907 
ubiquitin targets and the respective reader proteins, thereby enabling a coordinated 908 
downstream signalling output.  909 
The final actors involved in regulation of the ubiquitin code belong to a specific class 910 
of isopeptidases, named deubiquitinases (DUBs) which are able to hydrolyse 911 
ubiquitin linkages, therefore referred to as ‘erasers’ of the ubiquitin code. Certain 912 
proteins are believed to fulfil multiple of these functions with A20 perhaps being 913 
thought of as the most versatile player, as it has been suggested to act as writer, 914 
reader and eraser of the ubiquitin code. In TNF signalling, A20 has been proposed to 915 
negatively regulate NF-ĸB activation and death by removing K63-chains from RIPK1 916 
via its OTU domain and by subsequently K48-ubiquitinating RIPK1 via its ZnF4 [123, 917 
145]. Moreover, A20 can elicit DUB activity-independent functions. Importantly, wild 918 




































































death while a ZnF7 mutant of A20, which is not able to bind to linear ubiquitin chains, 920 
fails to do so, demonstrating that A20 can act as a scaffold/ubiquitin-protective 921 
protein [28, 124, 125, 146, 147]. Contrary to A20-deficent mice, A20 OTU mutant or 922 
A20 ZnF4 mutant mice do not develop any signs of inflammation [148-150]. The 923 
generation of ZnF7 mutant mice would thus likely unravel the physiological 924 






































































Do the TRAIL-R1 and TRAIL-R2 signalling complexes differ in composition and, if 
so, is differential complex formation regulated by ubiquitination? 
How and where is the TRAIL-induced necroptosis-mediating complex formed and 
how do ubiquitination events exactly regulate its formation and function? 
Do cFLIPL and cFLIPS differentially modulate TRAIL-induced gene activation and, if 
so, what is the contribution of ubiquitination to this difference? 
Is caspase-10 ubiquitinated upon TRAIL signalling and, if so, to what extent does 
this affect TRAIL-R signalling output? 
What are the specific roles of the LUBAC components SHARPIN and HOIL-1 in 
TRAIL signalling? 
What are the distinct molecular mechanisms underlying HOIP’s activity-dependent 
and -independent roles in TRAIL signalling? 
To which extent do cIAP1/2 affect TRAIL signalling independently of their role in 
HOIP recruitment? 
What are the molecular requirements for recruitment of Cullin-3, TRAF2/cIAPs to 
TRAIL complex I and II? 
What is the relative contribution of the different roles of A20 (writer, reader and 
eraser of the ubiquitin code) to its function in TRAIL signalling? 
How does the caspase substrate CYLD regulate TRAIL signalling? 
How do ubiquitin events impact on the cross-talk between cancer cells and their 
microenvironment in vivo? 
Outstanding Questions
Could ubiquitin modifiers and binders be used as biomarkers or possibly targets for 













































































































MARCH 8 (E3) TRAIL-R1  
(K273) 
K48? 
↓ Apoptosis  
Necroptosis N/D 
N/D [49] 
MKRN1 (E3) FADD 
K48? 
↓ Apoptosis  
Necroptosis N/D 
N/D [56] 






HECTD3 (E3) Caspase 8  
(K215) 
K63 
↓ Apoptosis  
Necroptosis N/D 
N/D [69] 
TRAF2 (E3) Caspase-8 
(K224/229/231) 
K48 
↓ Apoptosis  
↓ Necroptosis 







cIAP1/2 (E3) RIPK1? ↓ Apoptosis 
↓ Necroptosis 














Itch (E3) cFLIPL/S 
K48? 
↑ Apoptosis  
Necroptosis N/D 
N/D [84, 85, 
90] 




↓ Apoptosis  
Necroptosis N/D 














K63, M1 chains? 
 
 
↓ Apoptosis  
Necroptosis N/D 
 
 
 
↓ Cytokine 
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